<DOC>
	<DOCNO>NCT01450111</DOCNO>
	<brief_summary>Primary objective trial investigate pharmacokinetics single dose repeat dose application lacosamide healthy male Korean subject .</brief_summary>
	<brief_title>To Evaluate Pharmacokinetics Safety/Tolerability Lacosamide 3 Dosages Healthy Male Korean Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject healthy male 20 45 year age ( inclusive ) Subject clinically relevant cardiovascular , renal , gastrointestinal , hepatic , metabolic , endocrine , neurological , psychiatric abnormality general good health Subject normal body weight determine body mass index ( BMI ) 19 28 kgm^2 Subject Korean ( parent pure Korean ethnicity ) Subject history present psychiatric neurological condition , opinion Investigator , could jeopardize would compromise subject 's ability participate trial Subject know suspected drug hypersensitivity , particular trial medication Subject consume 40 g alcohol/day ( amount correspond 1 L beer/day 0.5 L wine/day 6 glass ( Ã  2cL ) liquor/day ) Subject donate blood comparable blood loss ( &gt; 400 mL ) within last 3 month prior Eligibility Assessment ( EA ) Subject smoke 5 cigarette per day do within 6 month prior EA . Subject consume 600 mg caffeine/day ( 200 mL coffee contain approximately 100 mg caffeine , 200 mL black tea approximately 30 mg , 200 mL cola approximately 20 mg ) Subject diet deviate notably `` normal '' amount protein , carbohydrate , fat , judge Investigator ( eg , vegetarian vegan ) Subject take herbal medicine therapy within 2 week prior first dose Subject clinically relevant allergy Subject take concomitant medication currently within 2 week prior first dose ( exception acetaminophen allow take orally 1000 mg per dose 48 hour prior commencement dose ) Subject positive test alcohol and/or drug ( urine test ) EA confinement Subject high risk behavior HIV Subject test positive HIV antibody ( HIV Ab ) , hepatitis B surface antigen ( HBs Ag ) , hepatitis C virus antibody ( HCV Ab ) Subject history present condition hepatic disorder , eg , clinically relevant liver enzyme increase ( alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] , alkaline phosphatase [ AP ] , gammaglutamyl transpeptidase [ GGT ] ) Subject transaminase ( either ALT AST ) 2 time upper limit normal range ( ULN ) confinement Subject clinically relevant outofrange value hematology include coagulation parameter , clinical chemistry , serology urinalysis parameter Subject clinically relevant abnormality physical examination vital sign Subject pulse rate rest le 45 bpm 100 bpm EA Subject systolic blood pressure low 100 mmHg high 160 mmHg diastolic blood pressure high 95 mmHg EA Subject clinically relevant finding ECG , second third degree atrioventricular ( AV ) block PR interval &gt; 220 m , prolongation QRS duration &gt; 110 m , QTcB ( Bazett correct ) interval 450 m clinically relevant ECG find EA Subject perform heavy physical exertion 2 day EA confinement Subject history present condition respiratory cardiovascular disorder , eg , cardiac insufficiency , coronary heart disease , hypertension , arrhythmia , tachyarrhythmia , status myocardial infarction Subject history present condition malignancy Subject history present condition seizure disorder Subject atrial fibrillation/flutter , ventricular tachyarrhythmia ( eg , ventricular tachycardia , ventricular fibrillation , abort cardiac arrest ) , symptomatic heart block Eligibility Assessment Visit , diagnose Brugada syndrome ( also know Sudden Unexpected Death Syndrome )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Lacosamide</keyword>
</DOC>